Clinical trials: Paclitaxel, completed
Non-small Cell Lung Cancer
Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer
The primary objective of this study is to determine the overall response rate (complete response + partial response) to a combination of bavituximab plus carboplatin and paclitaxel in patients with previously untreated locally…
- Trial name
- NCT00687817
- Testing
- bavituximab plus paclitaxel and carboplatin
- Where
- 9 sites in India
- Volunteers
- 49 people
- Sponsor
- Peregrine Pharmaceuticals
Non-squamous Non-small Cell Lung Cancer
Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer
The objective of this study is to assess the similarity between QL1101 and Avastin® respectively combined with chemotherapy in terms of efficacy and safety in patients with non-squamous non-small cell lung cancer.
- Trial name
- NCT03169335
- Testing
- QL1101, Avastin®, Paclitaxel
- Where
- 2 sites in China
- Volunteers
- 535 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin when given together with paclitaxel in treating patients with metastatic or unresectable solid tumor.
- Trial name
- NCT00087217
- Testing
- tanespimycin, paclitaxel, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Early Stage Breast Cancer
Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer
This research study is testing the safety and feasibility of delivering the 4 cycles of 'dose-dense' paclitaxel without the use of Neulasta (Pegfilgrastim) as a Granulocyte Colony-stimulating Factor (G-CSF) support.
- Trial name
- NCT02698891
- Testing
- Paclitaxel, Neulasta
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Dana-Farber Cancer Institute
Lung Cancer
BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)
The goal of this study is to find the highest tolerable dose of BAY 43-9006 (sorafenib) and bevacizumab that can be given with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC).
- Trial name
- NCT00533585
- Testing
- BAY 43-9006, Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor
A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel
This is a multicenter, open-label, 2-stage study with a 2-treatment period crossover design. Eligible participants are adults with cancer for whom weekly therapy with IV paclitaxel at a dose of 80 mg/m2 over 1 hour is indicated.
- Trial name
- NCT04035473
- Testing
- HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules
- Where
- 7 sites in Australia, New Zealand and 1 more
- Volunteers
- 42 people
- Sponsor
- Athenex, Inc.
Metastatic Breast Cancer
PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer
PAKT was an investigator-led, placebo-controlled, randomized phase II trial performed in 42 academic medical centers in the United Kindom, South Korea, France, Hungary, Romania, and Georgia.
- Trial name
- PAKT (NCT02423603)
- Testing
- Paclitaxel, AZD5363
- Where
- 46 sites in France, Georgia and 4 more
- Volunteers
- 71 people
- Sponsor
- Queen Mary University of London
Metastatic Pancreatic Cancer
Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients
The majority patients diagnosed with pancreatic cancer have metastatic disease at the time of diagnosis. The prognosis is extremely poor with a 5-year survival rate of less than 5%.
- Trial name
- PACT-ACT-v6 (NCT02707159)
- Testing
- Nab paclitaxel / gemcitabine
- Where
- Norway
- Volunteers
- 70 people
- Sponsor
- Helse Stavanger HF
Stenosis, Restenosis
Clinical Trial on Peripheral Arteries Treated With SeQuent® Please P Paclitaxel Coated Balloon Catheter
The aim of the study is to assess the safety and efficacy of the paclitaxelreleasing balloon catheter SeQuent® Please P to treat de novo and restenotic lesions in the superficial femoral artery and the proximal two segments of…
- Trial name
- ConSeQuent (NCT01970579)
- Testing
- Paclitaxel coated balloon, uncoated PTA catheter
- Where
- 7 sites in Germany
- Volunteers
- 153 people
- Sponsor
- B. Braun Melsungen AG
Metastatic Breast Cancer
Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer
Metastatic breast cancer (MBC) is an incurable disease and is needed to improve effective chemotherapy. Paclitaxel plus Gemcitabine (PG) combination chemotherapy is one of the preferred chemotherapeutic regimens for patients with…
- Trial name
- EG_PG (NCT02263495)
- Testing
- Paclitaxel, Eribulin, Gemcitabine
- Where
- 2 sites in South Korea
- Volunteers
- 118 people
- Sponsor
- Asan Medical Center
Unspecified Adult Solid Tumor, Protocol Specific
PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Phase I trial to study the effectiveness of combining PS-341 and combination chemotherapy in treating patients who have advanced solid tumors.
- Trial name
- NCT00028587
- Testing
- bortezomib, paclitaxel, carboplatin
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)
Coronary Artery Disease
The REALITY Study - Head-to-Head Comparison Between Cypher and Taxus
The main objective of this study is to compare the performance of the Cypher sirolimus-eluting and the Taxus paclitaxel-eluting stent systems in a prospective, multi-center, randomized clinical study.
- Trial name
- NCT00235092
- Testing
- Cypher Sirolimus-Eluting Stent, Taxus Paclitaxel-Eluting Stent
- Where
- France
- Volunteers
- 1,335 people
- Sponsor
- Cordis US Corp.
Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms
Station-Specific Lymph Node Metastasis After Neoadjuvant Chemoimmunotherapy for Middle Thoracic Esophageal Squamous Cell Carcinoma
Neoadjuvant chemoimmunotherapy (NCIT) is increasingly used for locally advanced esophageal squamous cell carcinoma (ESCC). However, the station-specific distribution of residual lymph node metastasis after NCIT remains…
- Conditions
- Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Metastasis
- Trial name
- NCT07902544
- Volunteers
- 717 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Metastatic Breast Cancer
An Early Phase Study of Abraxane Combined With Phenelzine Sulfate in Patients With Metastatic or Advanced Breast Cancer
This phase 1b study will determine the safety and efficacy of combined treatment of Abraxane and phenelzine sulfate (Nardil) for metastatic or locally advanced breast cancer.
- Trial name
- Epi-PRIMED (NCT03505528)
- Testing
- Nanoparticle albumin-bound paclitaxel, Phenelzine Sulfate
- Where
- 3 sites in Australia
- Volunteers
- 8 people
- Sponsor
- EpiAxis Therapeutics
Resectable Pancreatic Cancer
Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer
The main purpose of this research study is to evaluate whether Abraxane and gemcitabine are effective in treating patients with operable pancreatic cancer.
- Trial name
- NCT01298011
- Testing
- Gemcitabine and Abraxane
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Pancreatic Cancer Research Team
Early Triple Negative Breast Cancer
BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy
The purpose of this study is to assess efficacy of platinum-based neoadjuvant chemotherapy in correlation with BRCA1-associated DNA repair dysfunction in patients with early triple negative breast cancer.
- Trial name
- NCT01672671
- Testing
- Doxorubicin, Paclitaxel, Cisplatin
- Where
- Russia
- Volunteers
- 41 people
- Sponsor
- Russian Academy of Medical Sciences
Metastasis, Breast Cancer
A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated…
- Trial name
- ATTAIN (NCT02915744)
- Testing
- NKTR-102, Eribulin, Ixabepilone
- Where
- 56 sites in United States, Australia and 8 more
- Volunteers
- 178 people
- Sponsor
- Nektar Therapeutics
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer
This phase I trial studies best dose of ipatasertib and how well it works with carboplatin with or without paclitaxel in treating patients with triple negative breast cancer that has spread to other places in the body…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
- Trial name
- NCT03853707
- Testing
- Atezolizumab, Capecitabine, Carboplatin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- City of Hope Medical Center
Breast Cancer, Stage II Breast Cancer
Preoperative Herceptin and Navelbine for Breast Cancer
The purpose of this study is to find out what effects the preoperative combination therapy of herceptin and navelbine have on HER-2 positive breast cancer.
- Conditions
- Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
- Trial name
- NCT00148681
- Testing
- Herceptin, Navelbine, Doxorubicin
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Solid Tumours
Capivasertib China PK Study
This is an open-label, 2-part Phase I study to assess the PK, safety and tolerability of capivasertib as monotherapy and in combination with paclitaxel in Chinese participants with advanced solid tumours
- Trial name
- NCT04742036
- Testing
- Capivasertib, Paclitaxel
- Where
- China
- Volunteers
- 16 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.